This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Exametazime
- DrugBank Accession Number
- DB11179
- Background
Exametazime is a diagnostic radiopharmaceutical agent commonly used for the preparation of Tc99m Exametazime injection. It acts as a chelating agent for the radioisotope technetium-99m to form a cationic complex. It is used in the detection of altered regional cerebral perfusion and for the radiolabeling of autologous leukocytes.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Exametazime (DB11179)
- Weight
- Average: 272.393
Monoisotopic: 272.221226158 - Chemical Formula
- C13H28N4O2
- Synonyms
- Exametazima
- Exametazime
- External IDs
- DL HM-PAO
- DL-HM-PAO
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- International/Other Brands
- Drax Exametazime
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Exametazime HMPAO Injection, powder, lyophilized, for solution 1 mg/1 Intravenous Anazao Health Corporation 2012-07-01 Not applicable US 
- Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Exametazime HMPAO Exametazime (1 mg/1) Injection, powder, lyophilized, for solution Intravenous Anazao Health Corporation 2012-07-01 Not applicable US
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- G29272NCKL
- CAS number
- 105613-48-7
- InChI Key
- BPNZYADGDZPRTK-UDUYQYQQSA-N
- InChI
- InChI=1S/C13H28N4O2/c1-9(11(3)16-18)14-7-13(5,6)8-15-10(2)12(4)17-19/h9-10,14-15,18-19H,7-8H2,1-6H3/b16-11+,17-12+/t9-,10-/m1/s1
- IUPAC Name
- (E)-N-[(3R)-3-[(3-{[(2R,3E)-3-(hydroxyimino)butan-2-yl]amino}-2,2-dimethylpropyl)amino]butan-2-ylidene]hydroxylamine
- SMILES
- C[C@@H](NCC(C)(C)CN[C@H](C)C(\C)=N\O)C(\C)=N\O
References
- General References
- FDA Approved Drug Products: Drax Exametazime (kit for the preparation of technetium Tc99m exametazime for leukocyte labeling) for intravenous use [Link]
- External Links
- PubChem Substance
- 347911145
- ChemSpider
- 7830987
- 62153
- ChEBI
- 31586
- ChEMBL
- CHEMBL1615781
- Wikipedia
- Technetium_(99mTc)_exametazime
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Unknown Status Diagnostic Vascular Prosthesis Infection 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, lyophilized, for solution Intravenous 0.3 mg Injection, powder, for solution Intravenous Injection Intravenous 0.5 MG Injection, powder, for solution Intravenous 0.5 mg Injection, powder, lyophilized, for solution Intravenous 0.5 mg Powder Intravenous Injection, powder, lyophilized, for solution Intravenous 1 mg/1 Solution Intravenous 0.5 mg Kit Intravenous 500 Mikrogramm - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.25 mg/mL ALOGPS logP 0.59 ALOGPS logP 0.93 Chemaxon logS -3 ALOGPS pKa (Strongest Acidic) 9.68 Chemaxon pKa (Strongest Basic) 8.48 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 4 Chemaxon Polar Surface Area 89.24 Å2 Chemaxon Rotatable Bond Count 8 Chemaxon Refractivity 76.95 m3·mol-1 Chemaxon Polarizability 31.26 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0abc-0190000000-5aab34679afd62a1c7da Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-00di-0090000000-8c5b26f21a82d0bcadfd Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0006-0960000000-d2598af22bcf2936201b Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0005-2690000000-aa04f57751c85bfe2566 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0a4i-1900000000-fda560b4f3c02f4e0b46 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-022i-5920000000-d60a02bd695f8628fbcd Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 184.6763341 predictedDarkChem Lite v0.1.0 [M-H]- 171.79509 predictedDeepCCS 1.0 (2019) [M+H]+ 184.1138341 predictedDarkChem Lite v0.1.0 [M+H]+ 174.15309 predictedDeepCCS 1.0 (2019) [M+Na]+ 183.8804341 predictedDarkChem Lite v0.1.0 [M+Na]+ 181.01918 predictedDeepCCS 1.0 (2019)
Drug created at December 03, 2015 16:51 / Updated at May 14, 2021 01:05